Mannheim, Germany

Wolfgang Littmann

This inventor holds 4 USPTO granted patents. Top assignee: Basf Aktiengesellschaft. Active years: 1980-1988.


% Patents Active = 100.0

Average Co-Inventor Count = 2.8

ph-index = 2

Forward Citations = 5(Granted Patents)


Company Filing History:


Years Active: 1980-1988

Loading Chart...
4 patents (USPTO):Explore Patents

Title: Wolfgang Littmann: Innovator in Pyrazine Derivatives

Introduction

Wolfgang Littmann is a notable inventor based in Mannheim, Germany. He has made significant contributions to the field of chemistry, particularly in the development of pyrazine derivatives. With a total of 4 patents to his name, Littmann's work has implications in various applications, including pharmaceuticals.

Latest Patents

Littmann's latest patents include the preparation of 2-amino-3-cyano-5-dialkoxymethylpyrazines and their derivatives. These compounds are synthesized from a novel 3-halomethyl-5-dihalomethyl-2-aminopyrazine derivative. The process involves several intermediates and reactions, ultimately leading to compounds that serve as precursors for vitamin B1 synthesis.

Career Highlights

Wolfgang Littmann is associated with BASF Aktiengesellschaft, a leading chemical company. His work at BASF has allowed him to explore innovative chemical processes and contribute to advancements in the field. His expertise in pyrazine chemistry has positioned him as a key figure in his area of research.

Collaborations

Littmann has collaborated with notable colleagues such as Joachim Paust and Hartmut Leininger. These partnerships have fostered a collaborative environment that enhances the research and development of new chemical compounds.

Conclusion

Wolfgang Littmann's contributions to the field of chemistry, particularly through his patents and collaborations, highlight his role as an innovator. His work continues to influence the development of important chemical compounds.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…